7FAR
Crystal structure of PDE5A in complex with inhibitor L12
7FAR の概要
エントリーDOI | 10.2210/pdb7far/pdb |
分子名称 | cGMP-specific 3',5'-cyclic phosphodiesterase, ZINC ION, MAGNESIUM ION, ... (5 entities in total) |
機能のキーワード | hydrolase-inhibitor complex, hydrolase/inhibitor |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 40804.85 |
構造登録者 | |
主引用文献 | Wu, D.,Zheng, X.,Liu, R.,Li, Z.,Jiang, Z.,Zhou, Q.,Huang, Y.,Wu, X.N.,Zhang, C.,Huang, Y.Y.,Luo, H.B. Free energy perturbation (FEP)-guided scaffold hopping. Acta Pharm Sin B, 12:1351-1362, 2022 Cited by PubMed Abstract: Scaffold hopping refers to computer-aided screening for active compounds with different structures against the same receptor to enrich privileged scaffolds, which is a topic of high interest in organic and medicinal chemistry. However, most approaches cannot efficiently predict the potency level of candidates after scaffold hopping. Herein, we identified potent PDE5 inhibitors with a novel scaffold a free energy perturbation (FEP)-guided scaffold-hopping strategy, and FEP shows great advantages to precisely predict the theoretical binding potencies Δ between ligands and their target, which were more consistent with the experimental binding potencies Δ (the mean absolute deviations < 2 kcal/mol) than those Δ or Δ predicted by the MM-PBSA or MM-GBSA method. Lead had an IC of 8.7 nmol/L and exhibited a different binding pattern in its crystal structure with PDE5 from the famous starting drug tadalafil. Our work provides the first report the FEP-guided scaffold hopping strategy for potent inhibitor discovery with a novel scaffold, implying that it will have a variety of future applications in rational molecular design and drug discovery. PubMed: 35530128DOI: 10.1016/j.apsb.2021.09.027 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.40006470991 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
